Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the Screening Visit.~* Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.~* Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior to screening.~* All medications or interventions for epilepsy must be stable for at least 4 weeks prior to screening and expected to remain stable throughout the study.~* No cardiovascular or cardiopulmonary abnormality based on ECHO, ECG or physical examination.~* Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.~Key Exclusion Criteria:~* Pulmonary arterial hypertension.~* Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.~* Current or past history of glaucoma.~* Moderate or severe hepatic impairment.~* Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine.~* Currently receiving or has received stiripentol in the past 21 days prior to Screening.~* Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days.~* Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the Screening Visit.~* A clinically significant medical condition,that would interfere with study participation, collection of study data, or pose a risk to the subject.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- ZX008 - 0.8 mg/kg/day (Type: EXPERIMENTAL): ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
- ZX008 - 0.2 mg/kg/day (Type: EXPERIMENTAL): ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered twice a day (BID) in equally divided doses with food.

Based on this trial design, predict the completion outcome and termination type (if applicable).